Which international pharmaceutical company developed ensifentrine-Ohtuvayre?

Ensifentrine Inhalation Suspension Solution (Ensifentrine)-Ohtuvayre was developed by Verona Pharma, Inc., a UK-based biopharmaceutical company focused on developing innovative drugs for the treatment of respiratory diseases. Founded in 2005, Verona Pharma is committed to using its proprietary drug discovery platform to develop new drugs for respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. Ensifentrine is an important innovation of the company in the field of COPD treatment. It has a unique dual mechanism of action and can inhibit lung inflammation and airway spasm at the same time.

The development background of Ensifentrine is to respond to the clinical needs of COPD patients that cannot be adequately controlled by conventional treatments. COPD is currently one of the leading causes of death in patients worldwide. Although existing treatments such as inhaled beta2 agonists, anticholinergics, and inhaled steroids can alleviate symptoms to a certain extent, there are still a large number of patients who cannot fully control the disease. Through years of research, Verona Pharma scientists have discovered that Ensifentrine can effectively improve airway ventilation, reduce chronic inflammation, and relieve airway spasm by simultaneously inhibiting the activities of PDE3 and PDE4 enzymes, thereby improving the quality of life of COPD patients.

The drug development of Ensifentrine has received great attention from the industry because it fills an important gap in the treatment of COPD. Compared with other drugs, Ensifentrine's dual mechanism of action enables it to have stronger comprehensive efficacy in clinical application. In clinical trials, Ensifentrine has shown to be superior to traditional treatments, especially in relieving symptoms of acute exacerbations of COPD and improving lung function, showing significant advantages.

Currently,Ensifentrine has obtained a number of international patents and has entered the clinical promotion stage in multiple markets around the world. With the accumulation of more clinical data, Verona Pharma is expected to further expand the market application scope of Ensifentrine and bring new treatment options to COPD patients.

Reference materials:https://www.drugs.com/monograph/ensifentrine.html